<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607890</url>
  </required_header>
  <id_info>
    <org_study_id>J18102</org_study_id>
    <secondary_id>IRB00173534</secondary_id>
    <nct_id>NCT03607890</nct_id>
  </id_info>
  <brief_title>Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor</brief_title>
  <official_title>Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical activity of nivolumab and
      relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory
      to prior PD-(L)1 therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy</condition>
  <condition>MSI-H Tumors</condition>
  <arm_group>
    <arm_group_label>Nivolumab and Relatlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Patients will receive treatment every 28 days for up to 2 years. Nivolumab (480 mg) will be administered IV on day 1 (28 day cycle).</description>
    <arm_group_label>Nivolumab and Relatlimab</arm_group_label>
    <other_name>anti-PD-1, OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relatlimab</intervention_name>
    <description>Patients will receive treatment every 28 days up to 2 years. Relatlimab (160 mg) will be administered IV on day 1 (28 day cycle).</description>
    <arm_group_label>Nivolumab and Relatlimab</arm_group_label>
    <other_name>BMS-986016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Have metastatic or locally advanced mismatch repair deficient/MSI-H disease.

          -  Patients must have received prior PD-1/PD-L1 inhibitor therapy

          -  Have disease progression.

          -  Patients with the presence of at least one measurable lesion.

          -  Life expectancy of greater than 3 months.

          -  Patients must have adequate organ and marrow function defined by study - specified
             laboratory tests.

          -  Documented left ventricular ejection fraction (LVEF) ≥ 50% - 6 month prior to drug
             administration.

          -  Must use acceptable form of birth control while on study.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Known history or evidence of brain metastases.

          -  Require any antineoplastic therapy.

          -  History of prior treatment with anti-LAG3.

          -  Had chemotherapy, radiation, or steroids within 14 days prior to study treatment.

          -  Have received any investigational drugs, a live vaccine, any allergen
             hyposensitization therapy, growth factors or major surgery within 28 days prior to
             study treatment.

          -  Hypersensitivity reaction to any monoclonal antibody.

          -  Has uncontrolled intercurrent acute or chronic medical illness.

          -  Has an active known or suspected autoimmune disease.

          -  Has a diagnosis of immunodeficiency.

          -  Prior tissue or organ allograft or allogeneic bone marrow transplantation.

          -  Requires daily supplemental oxygen

          -  History of interstitial lung disease.

          -  Significant heart disease

          -  History of encephalitis, meningitis, or uncontrolled seizures in the year prior to
             informed consent.

          -  Infection with HIV or hepatitis B or C at screening.

          -  Has an active infection.

          -  Unable to have blood drawn.

          -  Patient with uncontrolled intercurrent illness including, but not limited to,
             uncontrolled infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Prior life-threatening toxicity to anti-PD-1, anti-PD-L1, anti-PD-L2,or anti-CTLA4

          -  Woman who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
    <phone>410-614-3644</phone>
    <email>Sartosu@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Zorzi, RN</last_name>
    <phone>410-614-5818</phone>
    <email>Jzorzi1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>Sartosu@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relatlimab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Anti - PD-1</keyword>
  <keyword>Anti - LAG-3</keyword>
  <keyword>Antibodies</keyword>
  <keyword>MSI</keyword>
  <keyword>MMR deficient</keyword>
  <keyword>Microsatellite instability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

